Actelion Pharmaceuticals Ltd

Type: Company
Name: Actelion Pharmaceuticals Ltd (Actelion Ltd)
Nationality: Switzerland
Web Address: http://www.actelion.com/
Fact Sheet: Fact Sheet for Actelion Ltd
First reported Sep 10 2014 - Updated Sep 10 2014 - 1 reports

Arena Pharmaceuticals - A Biotech Value Investment

Summary Why Arena is one of the best value investments in biotech. Update on the obesity market. Belviq lifecycle and Arena pipeline advancement.It has been some time since I have written an article covering Arena Pharmaceuticals (NASDAQ: ARNA ), and ... [Published Seeking Alpha - Sep 10 2014]
First reported Sep 09 2014 - Updated Sep 09 2014 - 1 reports

Patient-reported outcome tool for C. difficile -associated diarrhea accurately addressed patient experience

WASHINGTON, D.C. — Patients reported that a new patient-reported outcome assessment tool developed based on the FDA PRO Guidance for Industry was easy to understand and relevant to their experience of Clostridium difficile -related diarrhea symptoms, ... [Published Orthopedics Today - Sep 09 2014]
First reported Sep 05 2014 - Updated Sep 05 2014 - 1 reports

ACTELION : Europe's Largest Biopharmaceutical Company Takes Big Leap into Procurement-Powered Business Performance with Zycus

Headquartered in Allschwil/ Basel, Switzerland , Actelion has more than 30 operating affiliates around the world, including the United States , Canada , Brazil , Australia , Japan , Switzerland and a number of EU countries. In June 2013 Actelion began ... [Published 4 Traders - Sep 05 2014]
First reported Sep 04 2014 - Updated Sep 04 2014 - 3 reports

Actelion Pharmaceuticals US, Inc. Release: Europe's Largest Biopharmaceutical Company Takes Big Leap into Procurement-Powered Business Performance With

BASEL, Switzerland--(BUSINESS WIRE)--Zycus, a world leader in Procurement Technology solutions across the source-to-pay cycle, announced today that Actelion, Europe's largest biopharmaceutical company, will adopt its complete suite of procurement performance ... [Published BioSpace - Sep 04 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

Zurich Stocks Rise; Novartis Drug Test Results Eyed -- Market Talk

The SMI stocks index in Zurich adds 0.43% to 8658.97. Novartis rises 0.43% ahead of the results presentation for an important heart drug test at a European conference on Saturday. Fellow pharma giant Roche climbs 0.22%, while Actelion, Europe's biggest ... [Published 4 Traders - Aug 29 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Roche acquires InterMune for $8bn

Deal Date: Aug-01-2014 /Deal # 201410134Executive SummaryIn an all-cash deal Roche acquired former partner, public biotech InterMune Inc. (orphan respiratory/pulmonary and fibrotic disease therapeutics), for $8bn or $74 per share--a 47% premium and almost ... [Published Health News Daily - Aug 28 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 2 reports

Stifel Downgrades InterMune; Roche Offer 'Appropriate Ending'

Shares of InterMune (NASDAQ: ITMN) were downgraded to Hold from Buy by Stifel following Roche's proposed $8.3 billion acquisition over the weekend.InterMune has been the subject of various takeover rumors. On August 13, Bloomberg reported that Roche, ... [Published Benzinga.com - Aug 25 2014]
First reported Aug 21 2014 - Updated Aug 21 2014 - 4 reports

Research and Markets: Global Lysosomal Storage Diseases Market 2014-2018: Key Vendors are Actelion Pharmaceuticals, …

DUBLIN--(BUSINESS WIRE)--Research and Markets ( http://www.researchandmarkets.com/research/5f7fvn/global_lysosomal ) has announced the addition of the "Global Lysosomal Storage Diseases Market 2014-2018" report to their offering.The Global Lysosomal ... [Published Yahoo! Finance - Aug 21 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

Cardiac Arrhythmias and Defects in Systemic Sclerosis

Authors and DisclosuresAlessandra Vacca 1 , Christophe Meune 2 , Jessica Gordon 3 , Lorinda Chung 4,5 , Susanna Proudman 6 , Shervin Assassi 7 , Mandana Nikpour 8 , Tatiana S. Rodriguez-Reyna 9 , Dinesh Khanna 10 , Robert Lafyatis 11 , Marco Matucci-Cerinic ... [Published Theheart.org - Aug 20 2014]
First reported Aug 18 2014 - Updated Aug 19 2014 - 2 reports

NewLink Genetics Corp. (NLNK) Jumps: Stock Adds 8.6% in Session

NewLink Genetics Corporation ( NLNK ) was a big mover last session, as its shares rose almost 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend for the company, ... [Published Yahoo! Finance - Aug 18 2014]
First reported Aug 18 2014 - Updated Aug 19 2014 - 1 reports

Achillion Pharmaceuticals (ACHN) in Focus: Stock Up 9.6%

Achillion Pharmaceuticals ( ACHN ) was a big mover last session, as the company saw its shares gain nearly 10% on the day. This rally higher can be attributable to solid volume with far more shares changing hands than in a normal session. This continues ... [Published Yahoo! Finance - Aug 18 2014]
First reported Aug 18 2014 - Updated Aug 18 2014 - 2 reports

Global Lysosomal Storage Diseases Market 2014-2018: Key Vendors are Actelion, BioMarin, Genzyme and Shire

These deficiencies result in deficient enzymatic activity which, in turn, leads to accumulation of partially digested or undigested macromolecules inside the cell. The clinical manifestations of lysosomal storage diseases depend on the type of substrate ... [Published Indianapolis Business Journal - Aug 18 2014]

Quotes

"We were interested specifically in patients who were in care at the time of their death, because it's likely that this group would form the core of future potential donors" he said
That the drugs were combined is more important than the exact nature of the drugs used, she said. "I can't think of a rationale why one combination would work and another one wouldn't."

More Content

All (169) | News (136) | Reports (0) | Blogs (29) | Audio/Video (0) | Fact Sheets (2) | Press Releases (1)
sort by: Date | Relevance
United Therapeutics Points to Pluristem's PLX-P... [Published BioMedReports - 1 hour ago]
Study Dampens HOPE of HIV Organ Donations [Published General Medicine eJournal - Sep 15 2014]
Two Drugs Better Than 1 for Pulmonary Hypertension [Published American Journal of Public Health - Sep 15 2014]
Pharma deals during August 2014 [Published PMLive - Sep 11 2014]
Arena Pharmaceuticals - A Biotech Value Investment [Published Seeking Alpha - Sep 10 2014]
Ambrisentan/tadalafil combo could be PAH standa... [Published Pharma Times - Sep 10 2014]
Patient-reported outcome tool for C. difficile ... [Published Orthopedics Today - Sep 09 2014]
Career Moves: Intarcia Therapeutics Appoints Su... [Published India-West - Sep 05 2014]
ACTELION : Europe's Largest Biopharmaceutical C... [Published 4 Traders - Sep 05 2014]
Actelion Pharmaceuticals US, Inc. Release: Euro... [Published BioSpace - Sep 04 2014]
Europe's Largest Biopharmaceutical Company Take... [Published Street Sweeper - Sep 04 2014]
Europe's Largest Biopharmaceutical Company Take... [Published Yahoo! Finance - Sep 04 2014]
Roche CEO Schwan took a hands-on approach negot... [Published FierceBiotech - Sep 03 2014]
Medicines update (18) [Published Pharmacy News - Sep 03 2014]
BioSpecifics Technologies Corp. Announces Prese... [Published Reuters - Sep 02 2014]
Zurich Stocks Rise; Novartis Drug Test Results ... [Published 4 Traders - Aug 29 2014]
World Biotechnology Market Revenue Will Hit $60... [Published Benzinga.com - Aug 28 2014]
Roche acquires InterMune for $8bn [Published Health News Daily - Aug 28 2014]
Pharmaceutical, Biomedical, Healthcare Leaders ... [Published Prlog - Aug 27 2014]
With An Iffy Non-Oncology Pipeline, Roche Pays ... [Published Seeking Alpha - Aug 27 2014]
Roche to acquire 100% stake in InterMune [Published Individual.com - Aug 26 2014]
Roche pays $8.3bn for InterMune [Published Pharmafocus - Aug 26 2014]
Biotechs Rise After InterMune Acquired by Roche [Published The Street Latest - Aug 25 2014]
Stifel Downgrades InterMune; Roche Offer 'Appro... [Published Benzinga.com - Aug 25 2014]
InterMune's Roche Deal Sends Peer Group Up [Published Benzinga.com - Aug 25 2014]
Roche Buying InterMune for $8.3 Billion; Invest... [Published Yahoo! Finance - Aug 25 2014]
Roche In $8.3 Billion Deal To Acquire InterMune... [Published Value Walk - Aug 25 2014]
Roche to Expand Respiratory Role With $8.3 Bill... [Published Washington Post - Aug 25 2014]
Roche Agrees to Buy InterMune for $8.3 Billion ... [Published GARP - Aug 25 2014]
Pharma bidding war: Roche to pay $8.3bn for Int... [Published Telegraph - Aug 24 2014]
1 2 3 4 5 6
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Research and Markets: Global Lysosomal Storage ... [Published Business Wire Health News - Aug 21 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/5f7fvn/global_lysosomal) has announced the addition of the "Global Lysosomal Storage Diseases Market 2014-2018" report to their offering. The Global Lysosomal Storage ...
Global Lysosomal Storage Diseases Market 2014-2... [Published PR Newswire: General Business - Aug 18 2014]
DUBLIN, Aug. 18, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Lysosomal Storage Diseases Market 2014-2018" report to their offering. The term lysosomal storage diseases refers to a group of rare inherited disorders ...
Stop Abusing the Loophole! [Published The Big Red Biotech Blog - Aug 07 2014]
The US Treasury and lawmakers say they will push ahead with their attempts to prevent further tax inversion deals from proceeding --- and they will push to make this legislation retroactive to take away rewards accomplished deals may have already gleaned. ...
PatientsLikeMe and Actelion to Develop New Pati... [Published Business Wire Health News - Aug 05 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--PatientsLikeMe and Actelion Ltd. are partnering in a research initiative to create a new patient-reported outcomes tool for the rare form of non-Hodgkin's lymphoma called MF-CTCL. ...
[Department of Error] Department of Error [Published The Lancet - Jul 25 2014]
Devos P, Haeffner-Cavaillon N, Ledoux S, Balandier C, Ménard J. Assessing the French Alzheimer plan. Lancet 2014; 383: 1805—In this Correspondence (May 24), the declaration of interests should have read: “JM was involved in the design of the plan. JM ...
1 2 3 4 5 6

Press Releases

sort by: Date | Relevance
PatientsLikeMe and Actelion to Develop New Pati... [Published PatientsLikeMe Press Release - Aug 05 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.